Baxter International Inc vs Oxford Lane Capital Corp — how do they compare? Baxter International Inc trades at $26.76 (market cap $14.27B), while Oxford Lane Capital Corp trades at $9.48 (market cap $909.61M). The key difference: Baxter International Inc is far larger — about 15.7× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (25.76%). Which is the better fit depends on your goals.
| BAX | OXLC | |
|---|---|---|
Market Cap | $14.27B | $909.61M |
Sector | Health | Financials |
52-Week High | $28.35 | $18.75 |
52-Week Low | $15.80 | $8.15 |
Enterprise Value | $21.79B | — |
Dividend Yield | 0.14% | 25.76% |
Signals from Pluang's Aura AI — not financial advice
Baxter International Inc. (BAX) trades at $27.78, up 0.83% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat estimates with EPS of $0.56 versus $0.37 expected, and revenue guidance was raised, signaling operational improvement. However, the company posted a net loss of -$957 million in 2025, with negative profit margins and high P/E of 87.85, reflecting valuation concerns amid turnaround efforts.
The stock shows potential from earnings momentum and cost initiatives, but high debt and inconsistent profitability pose risks. Analyst consensus is mixed with a $25.43 price target below current levels, suggesting cautious optimism. Investors should weigh recent beats against structural challenges in the medtech sector.
OXLC trades at $9.43, up 1.73% today, with a bullish technical signal from moving averages but mixed oscillators. The stock shows a low P/B of 0.88 but high P/S of 92.8, with recent earnings misses and a volatile net income margin of 100.85% in 2026. Dividends of $0.20 monthly are ongoing, while news highlights NAV discounts and sustainability concerns.
Outlook is cautious due to earnings volatility and high yield risks; opportunities include deep NAV discounts, but risks involve unsustainable distributions and negative ROE/ROA. Analyst consensus is split, with 50% buy ratings reflecting divided sentiment on recovery potential versus financial instability.
Trailing returns across standard periods
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →